Shared Mechanisms of Antidepressant and Antiepileptic Treatments: Drugs and Devices

Clinical EEG and Neuroscience

Volumn 35, Issue 1, 2004, Pages 25-37

  Jobe, Phillip C ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Antidepressants; Antiepileptics; Corticotropin Releasing Hormone (CRH); GABAergic; Glutamatergic; Noradrenergic; Serotonergic; Vagus Nerve Stimulation

Indexed keywords

4 AMINOBUTYRIC ACID; AMITRIPTYLINE; AMOXAPINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CORTICOTROPIN RELEASING FACTOR; DESIPRAMINE; DOXEPIN; FLUOXETINE; GLUTAMIC ACID; IMIPRAMINE; MAPROTILINE; MONOAMINE OXIDASE INHIBITOR; NAPHTHALENE DERIVATIVE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PHENETHYLAMINE DERIVATIVE; PHENYTOIN; PROPYLAMINE; PROTRIPTYLINE; SELEGILINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TETRACYCLIC ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

DEVICE; DRUG HALF LIFE; DRUG MECHANISM; EPILEPSY; GABAERGIC SYSTEM; HUMAN; MOOD DISORDER; NONHUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; REVIEW; SEIZURE THRESHOLD; SEROTONINERGIC SYSTEM; VAGUS NERVE STIMULATION;

ANIMALS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; BRAIN; COMORBIDITY; DRUG THERAPY, COMBINATION; ELECTRIC STIMULATION THERAPY; EPILEPSY; HUMANS; MOOD DISORDERS; NEUROTRANSMITTER AGENTS; SYNAPTIC TRANSMISSION; VAGUS NERVE;

EID: 1842586129     PISSN: 15500594     EISSN: None     Source Type: Journal    
DOI: 10.1177/155005940403500109     Document Type: Article

References (221)

1. Dailey JW Naritoku DK. Antidepressants and seizures: Clinical anecdotes overshadow neuroscience. Biochem Pharmacol 1996; 52: 1323-1329.
2. Ballenger JC. The clinical use of carbamazepine in affective disorders. J Clin Psychiatry 1988; 49(suppl 1): 13-21.
3. Denicoff KD Smith-Jackson EE Disney ER Ali SO Leverich GS Post RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58(11): 470-478.
4. Dietrich DE Kropp S Emrich HM. Oxcarbazepine in affective and schizoaffective disorders. Pharmacopsychiatry 2001; 34(6): 242-250.
5. Ferrier IN. Developments in mood stabilisers. Br Med Bull 2001; 57: 179-192.
6. Post RM Uhde TW Ballenger JC. Efficacy of carbamazepine in affective disorders: Implications for underlying physiological and biochemical substrates. In: Emrich HM, Okuma T, Muller AA, (eds). Anticonvulsants in Affective Disorders. Amsterdam: Elsevier Science Publishers, B.V.; 1984: 93-115.
7. Post RM Ketter TA Pazzaglia PJ Denicoff K George MS Callahan A, et al. Rational polypharmacy in the bipolar affective disorders. Epilepsy Res 1996; 11(suppl): 153-180.
8. Walden J Hesslinger B. Value of old and new anticonvulsants in treatment of psychiatric diseases. Fortschr Neurol Psychiatr 1995; 63: 320-335.
9. Marangell LB Rush AJ George MS Sackeim HA Johnson CR Husain MM, et al. Vagus nerve stimulation (VNS) for major depressive episodes: One year outcomes. Biol Psychiatry 2002; 51(4): 280-287.
10. Rush AJ George MS Sackeim HA Marangell LB Husain MM Giller C, et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: A multicenter study. Biol Psychiatry 2000; 47(4): 276-286.
11. Schachter SC. Vagus nerve stimulation: Where are we? Curr Opin Neurol 2002; 15(2): 201-206.
12. Grunze H Walden J. Relevance of new and newly rediscovered anticonvulsants for atypical forms of bipolar disorder. J Affect Disord 2002; 72(suppl): 21.
13. Theodore W. Transcranial magnetic stimulation in epilepsy. In: McLean MJ, Engstrom S, Holcomb RR, (eds). Magnetotherapy: Potential Therapeutic Benefits and Adverse Effects. Nashville, TN: TFG Press; 2003: 233-246.
14. Post RM Speer AM. Repetitive transcranial magnetic stimulation (rTMS) of the brain in the treatment of affective disorders. In: McLean MJ, Engstrom S, Holcomb RR, (eds). Magnetotherapy Potential Therapeutic Benefits and Adverse Effects. Nashville, TN: TFG Press; 2003: 209-232.
15. Chweh AY Swinyard EA Wolf HH Kupferberg HJ. Correlations among minimal neurotoxicity, anticonvulsant activity, and displacing potencies in a3Hβflunitrazepam binding of benzodiazepines. Epilepsia 1983; 24: 668-677.
16. Krall RL Penry JK White BG Kupferberg HJ Swinyard EA. Antiepileptic drug development: II. Anticonvulsant drug screening. Epilepsia 1978; 19: 409-428.
17. Krall RL Penry JK Kupferberg HJ Swinyard EA. Antiepileptic drug development: I. History and a program for progress. Epilepsia 1978; 19: 393-408.
18. Kupferberg HJ. Antiepileptic drug development program: A cooperative effort of government and industry. Epilepsia 1989; 30(suppl 1): S51-S56.
19. Mulzac D Scott KR. Profile of anticonvulsant activity and minimal toxicity of methyl 4-[(p-chlorophenyl)amino]-6-methyl-2-oxo-cyclohex-3-en-1-oate and some prototype antiepileptic drugs in mice and rats. Epilepsia 1993; 34(6): 1141-1146.
20. Scott KR Edafiogho IO Richardson EL Farrar VA Moore JA Tietz EL, et al. Synthesis and anticonvulsant activity of enaminones. II. Further structure-activity correlations. J Med Chem 1993; 36(14): 1947-1955.
21. Jobe PC Picchioni AL Chin L. Role of brain norepinephrine in audiogenic seizure in the rat. J Pharmacol Exp Ther 1973; 184: 1-10.
22. Jobe PC Woods TW Dailey JW. Proconvulsant and anticonvulsant effects of tricyclic antidepressants in genetically epilepsy-prone rats. Epilepsy International Symposium 1983: 229. Abstract.
23. Dailey JW Jobe PC. Anticonvulsant drugs and the genetically epilepsy-prone rat. Fed Proc 1985; 44: 2640-2644.
24. Woods TW Dailey JW Reigel CE Jobe PC. Anticonvulsant and proconvulsant effects of doxepin in the genetically epilepsy-prone rat (GEPR). Fed Proc 1985; 44: 1107. Abstract.
25. Jobe PC Woods TW McNulty M Dailey JW. Anticonvulsant and proconvulsant effects of tricyclic antidepressants. Fed Proc 1984; 43: 569. Abstract.
26. Fromm GH Wessel HB Glass JD Alvin JD Van Horn G. Imipramine in absence and myoclonic-astatic seizures. Neurology 1978; 28(9 Pt 1): 953-957.
27. Fromm GH Amores CY Thies W. Imipramine in epilepsy. Arch Neurol 1972; 27: 198-204.
28. Ojemann LM Friel PN Trejo WJ Dudley DL. Effect of doxepin on seizure frequency in depressed epileptic patients. Neurology 1983; 33: 646-648.
29. Ojemann LM Baugh-Bookman C Dudley DL. Effect of psychotropic medications on seizure control in patients with epilepsy. Neurology 1987; 37(9): 1525-1527.
30. Loscher W Lehmann H Teschendorf HJ Traut M Gross G. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. J Pharmacol Exp Ther 1999; 288(3): 984-992.
31. Heninger GR. Antidepressants. In: Gelder MG, Lopez-Lbor JJ, Andreasen NC, (eds). New Oxford Textbook of Psychiatry; 2000: 1293-1305.
32. Favale E Rubino V Mainardi P Lunardi G Albano C. Anticonvulsant effect of fluoxetine in humans. Neurology 1995; 45: 1926-1927.
33. Browning RA Wood AV Merrill MA Dailey JW Jobe PC. Enhancement of the anticonvulsant effect of fluoxetine following blockade of 5-HT1A receptors. Eur J Pharmacol 1997; 336: 1-6.
34. Dailey JW Yan QS Mishra PK Burger RL Jobe PC. Effects of fluoxetine on convulsions and on brain serotonin as detected by microdialysis in genetically epilepsy-prone rats. J Pharmacol Exp Ther 1992; 260: 533-540.
35. Yan QS Jobe PC Dailey JW. Evidence that a serotonergic mechanism is involved in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats. Eur J Pharmacol 1993; 252(1): 105-112.
36. Yan QS Jobe PC Cheong JH Ko KH Dailey JW. Role of serotonin in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats. Naunyn Schmiedebergs Arch Pharmacol 1994; 350: 149-152.
37. Dailey JW Yan QS Adams-Curtis LE Ryu JR Ko KH Mishra PK, et al. Neurochemical correlates of antiepileptic drugs in the genetically epilepsy-prone rat (GEPR). Life Sci 1996; 58(4): 259-266.
38. Yan QS Jobe PC Dailey JW. Further evidence of anticonvulsant role for 5-hydroxytryptamine in genetically epilepsy-prone rats. Br J Pharmacol 1995; 115: 1314-1318.
39. Snead OC. Basic mechanisms of generalized absence seizures. Ann Neurol 1995; 37(2): 146-157.
40. Jobe PC Dailey JW. Genetically epilepsy-prone rats (GEPRs) in drug research. CNS Drug Rev 2000; 6(3): 241-260.
41. Coffey LL Reith MEA Chen NH Jobe PC Mishra PK. Amygdala kindling of forebrain seizures and the occurrence of brainstem seizures in genetically epilepsy-prone rats. Epilepsia 1996; 37(2): 188-197.
42. McNamara JO. Kindling model of epilepsy. Adv Neurol 1986; 44: 303-318.
43. Jobe PC Mishra PK Dailey JW Ko KH Reith MEA. Genetic predisposition to partial (focal) seizures and to generalized tonic/clonic seizures: Interactions between seizure circuitry of the forebrain and brainstem. In: Berkovic SF, Genton P, Hirsch E, Picard F, (eds). Genetics of Focal Epilepsies. Avignon, France: John Libbey & Company, Ltd.; 1999: 251-260.
44. Jobe PC. Are there specific anatomical and/or transmitter systems (cortical or subcortical) that should be targeted? Int Rev Neurobiol 2002; 49: 221-252.
45. Browning RA. Effect of lesions on seizures in experimental animals. In: Fromm GH, Faingold CL, Browning RA, Burnham WM, (eds). Epilepsy and the Reticular Formation: The Role of the Reticular Core in Convulsive Seizures. New York: Alan R. Liss; 1987: 137-162.
46. Browning RA. The electroshock model, neuronal networks and antiepileptic drugs. In: Faingold CL, Fromm GH, (eds). Drugs for Control of Epilepsy: Actions on Neuronal Networks Involved in Seizure Disorders. Boca Raton, Florida: CRC Press, Inc.; 1992: 195-211.
47. Burnham WM. Electrical stimulation studies: Generalized convulsions triggered from the brain-stem. In: Fromm GH, Faingold CL, Browning RA, Burnham WM, (eds). The Role of the Reticular Core in Convulsive Seizures. New York: Alan R. Liss; 1987: 25-38.
48. Burnham WM Browning RA. The reticular core and generalized convulsions: A unified hypothesis. In: Fromm GH, Faingold CL, Browning RA, Burnham WM, (eds). Epilepsy and the Reticular Formation: The Role of the Reticular Core in Convulsive Seizures. New York: Alan R. Liss; 1987: 193-201.
49. Fromm GH. The brain-stem and seizures: Summary and synthesis. In: Fromm GH, Faingold CL, Browning RA, Burnham WM, (eds). Epilepsy and the Reticular Formation: The Role of the Reticular Core in Convulsive Seizures. New York: Alan R. Liss, Inc.; 1987: 203-218.
50. Browning RA Nelson DK. Modification of electroshock and pentylenetetrazol seizure patterns in rats after precollicular transections. Exp Neurol 1986; 93: 546-556.
51. Browning RA. Role of the brain-stem reticular formation in tonic-clonic seizures: Lesion and pharmacological studies. Fed Proc 1985; 44: 2425-2431.
52. Merrill MA Clough RW Jobe PC Browning RA. Role of the superior colliculus and the intercollicular nucleus in the brainstem seizure circuitry of the genetically epilepsy-prone rat. Epilepsia 2003; 44(3): 305-314.
53. Chakravarty DN Faingold CL. Differential roles in the neuronal network for audiogenic seizures are observed among the inferior colliculus subnuclei and the amygdala. Exp Neurol 1999; 157(1): 135-141.
54. Faingold CL. Neuronal networks in the genetically epilepsy-prone rat. Adv Neurol 1999; 79: 311-321.
55. Faingold CL. Neuronal networks, epilepsy, and the action of antiepileptic drugs. In: Faingold CL, Fromm GH, (eds). Drugs for Control of Epilepsy: Actions on Neuronal Networks Involved in Seizure Disorders. Boca Raton: CRC Press; 1992: 1-21.
56. Faingold CL Randall ME. Neurons in the deep layers of superior colliculus play a critical role in the neuronal network for audiogenic seizures: Mechanisms for production of wild running behavior. Brain Res 1999; 815(2): 250-258.
57. Beitner-Johnson D Guitart X Nestler EJ. Dopaminergic brain reward regions of Lewis and Fischer rats display different levels of tyrosine hydroxylase and other morphine- and cocaine-regulated phosphoproteins. Brain Res 1991; 561(1): 147-150.
58. Berridge KC. Food reward: Brain substrates of wanting and liking. Neurosci Biobehav Rev 1996; 20(1): 1-25.
59. Berridge KC Robinson TE. What is the role of dopamine in reward: Hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 1998; 28(3): 309-369.
60. Dayan P Balleine BW. Reward, motivation, and reinforcement learning. Neuron 2002; 36(2): 285-298.
61. de la Fuente-Fernandez R Phillips AG Zamburlini M Sossi V Calne DB Ruth TJ, et al. Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res 2002; 136(2): 359-363.
62. Koob GF. Animal models of craving for ethanol. Addiction 2000; 95(suppl 2):S73-S81.
63. Salamone JD Correa M. Motivational views of reinforcement: Implications for understanding the behavioral functions of nucleus accumbens dopamine. Behav Brain Res 2002; 137(1-2): 3-25.
64. Schultz W. Getting formal with dopamine and reward. Neuron 2002; 36(2): 241-263.
65. Wise RA. Neurobiology of addiction. Curr Opin Neurobiol 1996; 6: 243-251.
66. Wise RA. Brain reward circuitry: Insights from unsensed incentives. Neuron 2002; 36(2): 229-240.
67. Lingford-Hughes A Nutt D. Neurobiology of addiction and implications for treatment. Br J Psychiatry 2003; 182: 97-100.
68. Naranjo CA Tremblay LK Busto UE. The role of the brain reward system in depression. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25(4): 781-823.
69. Brody AL Barsom MW Bota RG Saxena S. Prefrontal-subcortical and limbic circuit mediation of major depressive disorder. Semin Clin Neuropsychiatry 2001; 6(2): 102-112.
70. Drevets WC Bogers W Raichle ME. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol 2002; 12(6): 527-544.
71. Davidson RJ Lewis DA Alloy LB Amaral DG Bush G Cohen JD, et al. Neural and behavioral substrates of mood and mood regulation. Biol Psychiatry 2002; 52(6): 478-502.
72. Byrum CE Thompson JE Heinz ER Krishnan KR Tien RD. Limbic circuits and neuropsychiatric disorders: Functional anatomy and neuroimaging findings. Neuroimaging Clin N Am 1997; 7(1): 79-99.
73. Jobe PC Mishra PK Browning RA Wang C Adams-Curtis LE Ko KH, et al. Noradrenergic abnormalities in the genetically epilepsy-prone rat. Brain Res Bull 1994; 35(5-6): 493-504.
74. Jobe PC Brown RD Dailey JW. Effect of Ro 4-1284 on audiogenic seizure susceptibility and intensity in epilepsy-prone rats. Life Sci 1981; 28: 2031-2038.
75. Applegate CD Tecott LH. Global increases in seizure susceptibility in mice lacking 5-HT2C receptors: A behavioral analysis. Exp Neurol 1998; 154(2): 522-530.
76. Shouse MN Staba RJ Ko PY Saquib SF Farber PR. Monoamines and seizures: Microdialysis findings in locus ceruleus and amygdala before and during amygdala kindling. Brain Res 2001; 892(1): 176-192.
77. Wada Y Shiraishi J Nakamura M Hasegawa H. Prolonged but not acute fluoxetine administration produces its inhibitory effect on hippocampal seizures in rats. Psychopharmacology (Berl) 1995; 118: 305-309.
78. Applegate CD Burchfiel JL. Microinjections of GABA agonists into the amygdala complex attenuates kindled seizure expression in the rat. Exp Neurol 1988; 102: 185-189.
79. Avoli M. GABA-mediated synchronous potentials and seizure generation. Epilepsia 1996; 37: 1035-1042.
80. Faingold CL Marcinczyk MJ Casebeer DJ Randall ME Americ SP Browning RA. GABA in the inferior colliculus plays a critical role in control of audiogenic seizures. Brain Res 1994; 640: 40-47.
81. Faingold CL Gehlbach G Travis MA Caspary DM. Inferior colliculus neuronal response abnormalities in genetically epilepsy-prone rats: Evidence for a deficit of inhibition. Life Sci 1986; 39: 869-878.
82. Gale K. GABA and epilepsy: Basic concepts from preclinical research. Epilepsia 1992; 33(suppl 15): S3-12.
83. Gale K. Progression and generalization of seizure discharge: Anatomical and neurochemical substrates. Epilepsia 1988; 29(suppl 12): S15-S34.
84. Gale K. Role of GABA in the genesis of chemoconvulsant seizures. Toxicol Lett 1992; 64(5): 417-428.
85. During MJ Spencer DD. Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet 1993; 341: 1607-1610.
86. During MJ Ryder KM Spencer DD. Hippocampal GABA transporter function in temporal-lobe epilepsy [see comments], Nature 1995; 376: 174-177.
87. Faingold CL Naritoku DK Copley CA Randall ME Riaz A Anderson CA, et al. Glutamate in the inferior colliculus plays a critical role in audiogenic seizure initiation. Epilepsy Res 1992; 13: 95-105.
88. Flavin HJ Wieraszko A Seyfried TN. Enhanced aspartate release from hippocampal slices of epileptic (El) mice. J Neurochem 1991; 56: 1007-1011.
89. Mares P Chino M Kubova H Mathern P Veliky M. Convulsant action of systemically administered glutamate and bicuculline methiodide in immature rats. Epilepsy Res 2000; 42(2-3): 183-189.
90. Meldrum BS. The role of glutamate in epilepsy and other CNS disorders. Neurology 1994; 44: 14-23.
91. Piredda S Gale K. A crucial epileptogenic site in the deep prepiriform cortex. Nature 1985; 317: 623-625.
92. Wasterlain CG Liu H Mazarati AM Baldwin RA Shirasaka Y Katsumori H, et al. Self-sustaining status epilepticus: A condition maintained by potentiation of glutamate receptors and by plastic changes in substance P and other peptide neuromodulators. Epilepsia 2000; 41(suppl 6): S134-S143.
93. Baram TZ Schultz L. Corticotropin-releasing hormone is a rapid and potent convulsant in the infant rat. Dev Brain Res 1991; 61(1): 97-101.
94. Baram TZ Mitchell WG Brunson K Haden E. Infantile spasms: Hypothesis-driven therapy and pilot human infant experiments using corticotropin-releasing hormone receptor antagonists. Dev Neurosci 1999; 21(3-5): 281-289.
95. Weiss SR Post RM Gold PW Chrousos G Sullivan TL Walker D, et al. CRF-induced seizures and behavior: Interaction with amygdala kindling. Brain Res 1986; 372(2): 345-351.
96. Jobe PC Dailey JW Wernicke JF. A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders. Crit Rev Neurobiol 1999; 13(4): 317-356.
97. Neumeister A Praschak-Rieder N Hebetaelmann B Rao ML Gluck J Kasper S. Effects of tryptophan depletion on drug-free patients with seasonal affective disorder during a stable response to bright light therapy. Arch Gen Psychiatry 1997; 54(2): 133-138.
98. Neumeister A Turner EH Matthews JR Postolache TT Barnett RL Rauh M, et al. Effects of tryptophan depletion vs catecholamine depletion in patients with seasonal affective disorder in remission with light therapy. Arch Gen Psychiatry 1998; 55(6): 524-530.
99. Neumeister A Praschak-Rieder N Hesselmann B Vitouch O Rauh M Barocka A, et al. Rapid tryptophan depletion in drug-free depressed patients with seasonal affective disorder. Am J Psychiatry 1997; 154(8): 1153-1155.
100. Lam RW Tarn EM Grewal A Yatham LN. Effects of alpha-methyl-para-tyrosine-induced catecholamine depletion in patients with seasonal affective disorder in summer remission. Neuropsychopharmacology 2001; 25(suppl 5): S97-S101.
101. Berman RM Narasimhan M Miller HL Anand A Cappiello A Oren DA, et al. Transient depressive relapse induced by catecholamine depletion: Potential phenotypic vulnerability marker? Arch Gen Psychiatry 1999; 56(5): 395-403.
102. Brostedt EM Pedersen NL. Stressful life events and affective illness. Acta Psychiatr Scand 2003; 107(3): 208-215.
103. Schousboe A. Role of astrocytes in the maintenance and modulation of glutamatergic and GABAergic neurotransmission. Neurochem Res 2003; 28(2): 347-352.
104. Chittajallu R Braithwaite SP Clarke VR Henley JM. Kainate receptors: Subunits, synaptic localization and function. Trends Pharmacol Sci 1999; 20(1): 26-35.
105. Faingold CL Anderson Boersma CA Caspary DM. Involvement of GABA in acoustically-evoked inhibition in inferior colliculus neurons. Hear Res 1991; 52: 201-216.
106. Olsen RW De Lorey TM Gordey M Kang MH. GABA receptor function and epilepsy. Adv Neurol 1999; 79: 499-510.
107. Faingold CL. Role of GABA abnormalities in the inferior colliculus pathophysiology - audiogenic seizures. Hear Res 2002; 168(1-2): 223-237.
108. Benes FM Berretta S. GABAergic interneurons: Implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 2001; 25(1): 1-27.
109. Brunson KL Avishai-Eliner S Baram TZ. ACTH treatment of infantile spasms: Mechanisms of its effects in modulation of neuronal excitability. Int Rev Neurobiol 2002; 49: 185-197.
110. Habib KE Gold PW Chrousos GP. Neuroendocrinology of stress. Endocrinol Metab Clin North Am 2001; 30(3): 695-728.
111. Kawahara H Kawahara Y Westerink BH. The role of afferents to the locus coeruleus in the handling stress-induced increase in the release of noradrenaline in the medial prefrontal cortex: A dual-probe microdialysis study in the rat brain. Eur J Pharmacol 2000; 387(3): 279-286.
112. Schulz C Kretz M Lehnert H. Activation of noradrenergic neurons in the locus coeruleus by corticotropin-releasing hormone. Society for Neuroscience Abstracts 1993:19 Abstracts.
113. Chaouloff F. Serotonin, stress and corticoids. J Psychopharmacol 2000; 14(2): 139-151.
114. Kirby LG Rice KC Valentino RJ. Effects of corticotropin-releasing factor on neuronal activity in the serotonergic dorsal raphe nucleus. Neuropsychopharmacology 2000; 22(2): 148-162.
115. Sanacora G Mason GF Rothman DL Hyder F Ciarcia JJ Ostroff RB, et al. Increased cortical GABA concentrations in depressed patients receiving ECT Am J Psychiatry 2003; 160(3): 577-579.
116. Massat I Souery D Del Favero J Oruc L Noethen MM Blackwood D, et al. Excess of allele1 for alpha3 subunit GABA receptor gene (GABRA3) in bipolar patients: A multicentric association study. Mol Psychiatry 2002; 7(2): 201-207.
117. Heckers S Stone D Walsh J Shick J Koul P Benes FM. Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. Arch Gen Psychiatry 2002; 59(6): 521-529.
118. Cotter D Landau S Beasley C Stevenson R Chana G MacMillan L, et al. The density and spatial distribution of GABAergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia. Biol Psychiatry 2002; 51(5): 377-386.
119. Duffy A Turecki G Grof P Cavazzoni P Grof E Joober R, et al. Association and linkage studies of candidate genes involved in GABAergic neurotransmission in lithium-responsive bipolar disorder. J Psychiatry Neurosci 2000; 25(4): 353-358.
120. Squires RF Saederup E. A review of evidence for GABAergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: More support for a continuum hypothesis of “functional” psychosis. Neurochem Res 1991; 16(10): 1099-1111.
121. Bjork JM Moeller FG Kramer GL Kram M Suris A Rush AJ, et al. Plasma GABA levels correlate with aggressiveness in relatives of patients with unipolar depressive disorder. Psychiatry Res 2001; 101(2): 131-136.
122. Shiah IS Yatham LN. GABA function in mood disorders: An update and critical review. Life Sci 1998; 63(15): 1289-1303.
123. Kalen P Strecker RE Rosengren E Bjorklund A. Regulation of striatal serotonin release by the lateral habenula- dorsal raphe pathway in the rat as demonstrated by in vivo micro-dialysis: Role of excitatory amino acids and GABA. Brain Res 1989; 492: 187-202.
124. Bonanno G Raiteri M. Release-regulating GABAA receptors are present on noradrenergic nerve terminals in selective areas of the rat brain. Synapse 1987; 1(3): 254-257.
125. Aston-Jones G Shipley MT Chouvet G Ennis M van Bockstaele E Pieribone V, et al. Afferent regulation of locus coeruleus neurons: Anatomy, physiology and pharmacology. Prog Brain Res 1991; 88: 47-75.
126. Shefner SA Osmanovic SS. GABAA and GABAB receptors and the ionic mechanisms mediating their effects on locus coeruleus neurons. Prog Brain Res 1991; 88: 187-195.
127. Kasckow JW Baker D Geracioti TD Jr. Corticotropin-releasing hormone in depression and post-traumatic stress disorder. Peptides 2001; 22(5): 845-851.
128. Gold PW Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: High vs low CRH/NE states. Mol Psychiatry 2002; 7(3): 254-275.
129. Nemeroff CB. New directions in the development of antidepressants: The interface of neurobiology and psychiatry. Hum Psychopharmacol 2002; 17(suppl 1): S13-S16.
130. Alda M Turecki G Grof P Cavazzoni P Duffy A Grof E, et al. Association and linkage studies of CRH and PENK genes in bipolar disorder: A collaborative IGSLI study. Am J Med Genet 2000; 96(2): 178-181.
131. Hatalski CG Guirguis C Baram TZ. Corticotropin releasing factor mRNA expression in the hypothalamic paraventricular nucleus and the central nucleus of the amygdala is modulated by repeated acute stress in the immature rat. J Neuroendocrinol 1998; 10(9): 663-669.
132. Hand GA Hewitt CB Fulk LJ Stock HS Carson JA Davis JM, et al. Differential release of corticotropin-releasing hormone (CRH) in the amygdala during different types of stressors. Brain Res 2002; 949(1-2): 122-130.
133. Bel N Artigas F. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 1993; 15: 243-245.
134. Itoh Y Oishi R Nishibori M Saeki K. In vivo measurement of noradrenaline and 3,4- dihydroxyphenylethyleneglycol in the rat hypothalamus by microdialysis: Effects of various drugs affecting noradrenaline metabolism, J Pharmacol Exp Ther 1990; 255: 1090-1097.
135. Kreiss DS Lucki I. Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J Pharmacol Exp Ther 1995; 274: 866-876.
136. Moret C Briley M. Effects of acute and repeated administration of citalopram on extracellular levels of serotonin in rat brain. Eur J Pharmacol 1996; 295: 189-197.
137. Ramaiya A Johnson JH Karnes HT. Evaluation of the neuropharmacodynamics of paroxetine in vivo utilizing microdialysis. J Pharm Sci 1997; 86(12): 1497-1500.
138. Yan QS Jobe PC Dailey JW. Noradrenergic mechanisms for the anticonvulsant effects of desipramine and yohimbine in genetically epilepsy-prone rats: Studies with microdialysis. Brain Res 1993; 610: 24-31.
139. Yan QS Burger R Jobe PC Dailey JW. Anticonvulsant doses of fluoxetine increase dialyzable serotonin from the thalamus of genetically epilepsy-prone rats (GEPRs). FASEB J Abstract 1990; 4(3 part 1): 465. Abstract.
140. Jobe PC Picchioni AL Chin L. Role of brain 5-hydroxytryptamine in audiogenic seizure in the rat. Life Sci 1973; 13: 1-13.
141. Jobe PC. Relationship of brain amine metabolism to audiogenic seizure in the rat. Diss Abs Int 1970; 31: 5. Abstract.
142. Mishra PK Kahle EH Bettendorf AF Dailey JW Jobe PC. Anticonvulsant effects of intracerebroventricularly administered norepinephrine are potentiated in the presence of monoamine oxidase inhibition in severe seizure genetically epilepsy-prone rats (GEPR-9s). Life Sci 1993; 52: 1435-1441.
143. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: Depression and anxiety disorders. In: Hardman JG, Limbird LE, (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 2001: 447-483.
144. Finberg JPM Pacak K Kopin IJ Goldstein DS. Chronic inhibition of monoamine oxidase type-a increases noradrenaline release in rat frontal cortex. Naunyn Schmiedebergs Arch Pharmacol 1993; 347: 500-505.
145. Boyer P Briley M. Milnacipran, a new specific serotonin and noradrenaline reuptake inhibitor. Drugs of Today 1988; 34: 709-720.
146. Briley M Prost JF Moret C. Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol 1996; 11(suppl 4): 9-14.
147. Palvimaki EP Laakso A Kuoppamaki M Syvalahti E Hietala J. Up-regulation of beta 1-adrenergic receptors in rat brain after chronic citalopram and fluoxetine treatments. Psychopharmacology 1994; 115: 543-546.
148. Page ME Abercrombie ED. An analysis of the effects of acute and chronic fluoxetine on extracellular norepinephrine in the rat hippocampus during stress. Neuropsychopharmacology 1997; 16(6): 419-425.
149. Seo DO Shin CY Lee CJ Dailey JW Reith MEA Jobe PC, et al. Effect of alterations in extracellular norepinephrine on adrenoceptors: A microdialysis study in freely moving rats. Eur J Pharmacol 1999; 365: 39-46.
150. Seo DO Shin CY Ryu JR Cheong JH Choi CR Dailey JW, et al. Effect of norepinephrine release on adrenoceptors in severe seizure genetically epilepsy-prone rats. Eur J Pharmacol 2000; 396(2-3): 53-58.
151. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: Depression and mania, In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, (eds). The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 1996: 431-459.
152. Meijer JH Groos GA. Responsiveness of suprachiasmatic and ventral lateral geniculate neurons to serotonin and imipramine: A microiontophoretic study in normal and imipramine-treated rats. Brain Res Bull 1988; 20(1): 89-96.
153. Menkes DB Aghajanian GK. Alpha 1-Adrenoceptor-mediated responses in the lateral geniculate nucleus are enhanced by chronic antidepressant treatment. Eur J Pharmacol 1981; 74: 27-35.
154. Menkes DB Aghajanian GK McCall RB. Chronic antidepressant treatment enhances alpha-adrenergic and serotonergic responses in the facial nucleus. Life Sci 1980; 27: 45-55.
155. Svensson TH Dahlof C Engberg G Hallberg H. Central pre-and postsynaptic monoamine receptors in antidepressant therapy. Acta Psychiatr Scand Suppl 1981; 290: 67-78.
156. Blier P de Montigny C. Effect of chronic tricyclic antidepressant treatment on the serotonergic autoreceptor: A microiontophoretic study in the rat. Arch Pharm 1980; 314: 123-128.
157. Browning RA Wade DR Marcinczyk M Long GL Jobe PC. Regional brain abnormalities in norepinephrine uptake and dopamine beta-hydroxylase activity in the genetically epilepsy- prone rat. J Pharmacol Exp Ther 1989; 249: 229-235.
158. Dailey JW Jobe PC. Indices of noradrenergic function in the central nervous system of seizure-naive genetically epilepsy-prone rats. Epilepsia 1986; 27(6): 665-670.
159. Faingold CL. The genetically epilepsy-prone rat. Gen Pharmacol 1988; 19: 331-338.
160. Jobe PC Laird HE Ko KH Ray T Dailey JW. Abnormalities in monoamine levels in the central nervous system of the genetically epilepsy-prone rat. Epilepsia 1982; 23(4): 359-366.
161. Mishra PK Dailey JW Reigel CE Jobe PC. Brain norepinephrine and convulsions in the genetically epilepsy- prone rat: Sex-dependent responses to Ro 4-1284 treatment. Life Sci 1988; 42: 1131-1137.
162. Nicoletti F Barbaccia ML Ladarola MJ Pozzi O Laird HE. Abnormality of alpha 1-adrenergic receptors in the frontal cortex of epileptic rats. J Neurochem 1986; 46: 270-273.
163. Dailey JW Reigel CE Mishra PK Jobe PC. Neurobiology of seizure predisposition in the genetically epilepsy-prone rat. Epilepsy Res 1989; 3: 3-17.
164. Dailey JW Mishra PK Ko KH Penny JE Jobe PC. Noradrenergic abnormalities in the central nervous system of seizure-naive genetically epilepsy-prone rats. Epilepsia 1991; 32: 168-173.
165. Dailey JW Mishra PK Ko KH Penny JE Jobe PC. Serotonergic abnormalities in the central nervous system of seizure-naive genetically epilepsy-prone rats. Life Sci 1992; 50: 319-326.
166. Jobe PC Ko KH Dailey JW. Abnormalities in norepinephrine turnover rate in the central nervous system of the genetically epilepsy-prone rat. Brain Res 1984; 290: 357-360.
167. Jobe PC Ray TB. Effects of norepinephrine and 5-hydroxytryptamine reuptake inhibitors on electrically-induced spinal cord seizures in rats. Res Commun Chem Pathol Pharmacol 1980; 30: 185-188.
168. Jobe PC Ray TB. The effects of reserpine, iproniazid and L-dopa on electrically- induced spinal cord seizures. Res Commun Chem Pathol Pharmacol 1980; 29: 417-427.
169. Yan QS Mishra PK Burger RL Bettendorf AF Jobe PC Dailey JW. Evidence that carbamazepine and antiepilepsirine may produce a component of their anticonvulsant effects by activating serotonergic neurons in genetically epilepsy-prone rats. J Pharmacol Exp Ther 1992; 261: 652-659.
170. Stull RE Jobe PC Geiger PF Ferguson GG. Letter: Effects of dopamine receptor stimulation and blockade on Ro 4-1284-induced enhancement of electroshock seizure. J Pharm Pharmacol 1973; 25: 842-844.
171. Jobe PC Picchioni AL Chin L. Enhancement of audiogenic seizure by modification of brain amine metabolism. Fed Proc 1969; 28: 795. Abstract.
172. Schlesinger K Boggan WO Freedman DX. Genetics of audiogenic seizures: I. Relation to brain serotonin and norepinephrine in mice. Life Sci 1965; 4: 2345-2351.
173. Kellogg C. Serotonin metabolism in the brains of mice sensitive or resistant to audiogenic seizures. J Neurobiol 1971; 2: 209-219.
174. Lehmann A. Audiogenic seizures data in mice supporting new theories of biogenic amines mechanisms in the central nervous system. Life Sci 1967; 6: 1423-1431.
175. Shaywitz BA Yager RD Gordon JW. Ontogeny of brain catecholamine turnover and susceptibility to audiogenic seizures in DBA/2J mice. Dev Psychobiol 1978; 11: 243-250.
176. Laird HE Dailey JW Jobe PC. Neurotransmitter abnormalities in genetically epileptic rodents. Fed Proc 1984; 43: 2505-2509.
177. Browning RA Clark KB Naritoku DK Smith DC Jensen RA. Loss of anticonvulsant effect of vagus nerve stimulation in the pentylenetetrazol seizure model following treatment with 6-hydroxydopamine or 5,7-dihydroxytryptamine. Society for Neuroscience 1997; 23: 2424. Abstract.
178. Krahl SE Clark KB Smith DC Browning RA. Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation. Epilepsia 1998; 39(7): 709-714.
179. Naritoku DK Terry WJ Helfert RH. Regional induction of fos immunoreactivity in the brain by anticonvulsant stimulation of the vagus nerve. Epilepsy Res 1995; 22: 53-62.
180. Jobe PC Deoskar VU Burger RL Dailey JW Ko KH Mishra PK. Norepinephrine and serontonin release during seizures in GEPRs and non-epileptic rats: Analysis of one minute microdialysis samples. Society for Neuroscience Abstracts 1995; 21(3): 1966. Abstract.
181. Jobe PC Ko KH Mishra PK. Norepinephrine release during seizures in GEPR and non-epileptic rats: Analysis of one minute microdialysis samples. Epilepsia 1995; 36(4): 18. Abstract.
182. Kokaia M Kalen P Bengzon J Lindvall O. Noradrenaline and 5-hydroxytryptamine release in the hippocampus during seizures induced by hippocampal kindling stimulation: An in vivo microdialysis study. Neuroscience 1989; 32(3): 647-656.
183. Ishihara K Sasa M. Mechanism underlying the therapeutic effects of electroconvulsive therapy (ECT) on depression. Jpn J Pharmacol 1999; 80(3): 185-189.
184. MacDonald RL. Is there a mechanistic basis for rational polypharmacy? Epilepsy Res 1996; 11(suppl): 79-93.
185. Cavalheiro EA Filho Calderazzo LS Bortolotto ZA Mello L Turski L. Anticonvulsant role of adenosine. Pol J Pharmacol Pharm 1987; 39: 537-543.
186. Faingold CL Browning RA. Mechanisms of anticonvulsant drug action. I. Drugs primarily used for generalized tonic-clonic and partial epilepsies. Eur J Pediatr 1987; 146: 2-7.
187. Meldrum BS. Excitatory amino acid transmitters in epilepsy. Epilepsia 1991; 32(suppl 12): S1-S3.
188. McLean MJ MacDonald RL. Multiple actions of phenytoin on mouse spinal cord neurons in cell culture. J Pharmacol Exp Ther 1983; 227: 779-789.
189. McLean MJ MacDonald RL. Carbamazepine and 10,11-epoxycarbamazepine produce use- and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986; 238: 727-738.
190. MacDonald RL Barker JL. Enhancement of GABA-mediated postsynaptic inhibition in cultured mammalian spinal cord neurons: A common mode of anticonvulsant action. Brain Res 1979; 167: 323-336.
191. Twyman RE Rogers CJ MacDonald RL. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol 1989; 25: 213-220.
192. Dailey JW Reith MEA Yan QS Li MY Jobe PC. Anticonvulsant doses of carbamazepine increase hippocampal extracellular serotonin in genetically epilepsy-prone rats: Dose response relationships. Neurosci Lett 1997; 227(1): 13-16.
193. Dailey JW Reith ME Steidley KR Milbrandt JC Jobe PC. Carbamazepine-induced release of serotonin from rat hippocampus in vitro. Epilepsia 1998; 39(10): 1054-1063.
194. Dailey JW Reith ME Yan QS Li MY Jobe PC. Carbamazepine increases extracellular serotonin concentration: Lack of antagonism by tetrodotoxin or zero Ca2+. Eur J Pharmacol 1997; 328(2-3): 153-162.
195. Southam E Kirkby D Higgins GA Hagan RM. Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats. Eur J Pharmacol 1998; 358(1): 19-24.
196. Biggs CS Pearce BR Fowler LJ Whitton PS. Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain: An in vivo microdialysis study. J Neurochem 1992; 59: 1702-1708.
197. Whitton PS Fowler LJ. The effect of valproic acid on 5-hydroxytryptamine and 5-hydroxyindoleacetic acid concentration in hippocampal dialysates in vivo. Eur J Pharmacol 1991; 200: 167-169.
198. Okada M Kaneko S Hirano T Ishida M Kondo T Otani K, et al. Effects of zonisamide on extracellular levels of monoamine and its metabolite, and on Ca-2+ dependent dopamine release. Epilepsy Res 1992; 13: 113-119.
199. Okada M Hirano T Kawata Y Murakami T Wada K Mizuno K, et al. Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Epilepsy Res 1999; 34(2-3): 187-197.
200. Kaneko S Okada M Hirano T Kondo T Otani K Fukushima Y. Carbamazepine and zonisamide increase extracellular dopamine and serotonin levels in vivo, and carbamazepine does not antagonize adenosine effect in vitro: Mechanisms of blockade of seizure spread. Jpn J Psychiatry Neurol 1993; 47(2): 371-373.
201. Barry JJ Lembke A Huynh N. Affective disorders in epilepsy. In: Ettinger AB, Kanner AM, (eds). Psychiatric Issues in Epilepsy: A Practical Guide to Diagnosis and Treatment. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001: 45-71.
202. Guerrini R Belmonte A Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia 1998; 39(suppl 3): S2-S10.
203. Kochen S Giagante B Oddo S. Spike-and-wave complexes and seizure exacerbation caused by carbamazepine. Eur J Neurol 2002; 9(1): 41-47.
204. Adverse reactions to antiepileptic drugs: A follow-up study of 355 patients with chronic antiepileptic drug treatment. Collaborative Group for Epidemiology of Epilepsy. Epilepsia 1988; 29(6): 787-793.
205. Bauer J. Seizure-inducing effects of antiepileptic drugs: A review. Acta Neurol Scand 1996; 94(6): 367-377.
206. Snead OC Hosey LC. Exacerbation of seizures in children by carbamazepine. N Engl J Med 1985; 313: 916-921.
207. Buckley NA Dawson AH Whyte IM Henry DA. Greater toxicity in overdose of dothiepin than of other tricyclic antidepressants. Lancet 1994; 343: 159-162.
208. Alldredge BK. Seizure risk associated with psychotropic drugs: Clinical and pharmacokinetic considerations. Neurology 1999; 53(suppl 2): S68-S75.
209. Curran S de Pauw K. Selecting an antidepressant for use in a patient with epileps: Safety considerations. Drug Safety 1998; 18(2): 125-133.
210. Pisani F Spina E Oteri G. Antidepressant drugs and seizure susceptibility: From in vitro data to clinical practice. Epilepsia 1999; 40(suppl 10): S48-S56.
211. Pisani F Oteri G Costa C Di Raimondo G Di Perri R. Effects of psychotropic drugs on seizure threshold. Drug Safety 2002; 25(2): 91-110.
212. Trimble MR. Antidepressant drugs and convulsions. Lancet 1980; 1: 307.
213. Trimble MR. New antidepressant drugs and the seizure threshold. Neuropharmacology 1980; 19: 1227-1228.
214. Wong IC Lhatoo SD. Adverse reactions to new anticonvulsant drugs. Drug Safety 2000; 23(1): 35-56.
215. Spiller HA. Management of carbamazepine overdose. Pediatr Emerg Care 2001; 17(6): 452-456.
216. Spiller HA Carlisle RD. Status epilepticus after massive carbamazepine overdose. J Toxicol Clin Toxicol 2002; 40(1): 81-90.
217. Osorio I Peltzer J Reed R. Carbamazepine and phenytoin exacerbate primary generalized epilepsy. Epilepsia 1996; 37(suppl 5): 93. Abstract.
218. Osorio I Burnstine TH Remler B Manon-Espaillat R Reed RC. Phenytoin-induced seizures: A paradoxical effect at toxic concentrations in epileptic patients. Epilepsia 1989; 30(2): 230-234.
219. Bourn WM Garrett RL Reigel CE Risinger FO. Reduction of flurazepam convulsive threshold by Ro 15-1788. Psychopharmacology 1985; 85: 267-270.
220. Spiller HA Ramoska EA Krenzelok EP Sheen SR Borys DJ Villalobos D, et al. Bupropion overdose: A 3-year multi-center retrospective analysis. Am J Emerg Med 1994; 12: 43-45.
221. Garrett RL Bourn WM. Convulsant component of a depressant benzodiazepine. Life Sci 1985; 37; 1933-1939.